A phase I/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer
Name:
36378548.pdf
Size:
6.655Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Jones, R.Plummer, R.
Moreno, V.
Carter, Louise
Roda, D.
Garralda, E.
Kristeleit, R.
Sarker, D.
Arkenau, T.
Roxburgh, P.
Walter, H. S.
Blagden, S.
Anthoney, A.
Klencke, B. J.
Kowalski, M. M.
Banerji, U.
Affiliation
Cardiff University and Velindre NHS Trust, Cardiff, United KingdomIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: This was a phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish the safety profile, recommended phase 2 dose (RP2D), pharmacokinetics profile, and clinical activity of SRA737. Patients and methods: Patients with advanced solid tumors were enrolled into dose-escalation cohorts and treated in 28-day cycles with oral SRA737 on days 2, 3, 9, 10, 16 and 17, and intravenous gemcitabine on days 1, 8 and 15. Treatment was continued until progression. Each expansion cohort included up to 20 patients with specific genetically defined tumors. Results: The RP2D was determined to be 500 mg SRA737 combined with low-dose (250 mg/m2) gemcitabine. Of 143 enrolled patients, 77 were treated at doses of at least 500 mg SRA737 combined with 250 mg/m2 gemcitabine. Common toxicities of nausea, vomiting, fatigue and diarrhea were primarily mild to moderate, and rarely led to treatment discontinuation. Anemia, neutropenia and thrombocytopenia were grade ≥3 in 8.3% to 11.7% of patients treated at the RP2D. The objective response rate (ORR) was 10.8% overall and notably the ORR in anogenital cancer was 25%. Partial tumor responses were observed in anogenital cancer, cervical cancer, high-grade serous ovarian cancer, rectal cancer, and small cell lung cancer. Conclusions: SRA737 in combination with low-dose gemcitabine was well tolerated with lower myelotoxicity than has been seen at standard doses of gemcitabine or with other combinations of Chk1 inhibitors with gemcitabine. Tumor responses were observed in anogenital and other solid tumors.Citation
Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, et al. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Nov 15. PubMed PMID: 36378548. Epub 2022/11/16. eng.Journal
Clinical Cancer ResearchDOI
10.1158/1078-0432.ccr-22-2074PubMed ID
36378548Additional Links
https://dx.doi.org/10.1158/1078-0432.ccr-22-2074Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.ccr-22-2074